Skip to content
DataLookout
Menu

GC4006ANCT07936188

Phase 2 Study of GC4006A in Healthy Adults

StatusEnrolling by Invitation
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Differences between groups of Neutralizing Antibody Responses
Timeframe: up to 4 weeks
Differences between groups of Binding Antibody Responses
Timeframe: up to 4 weeks

Secondary (7)

Differences between groups of Neutralizing Antibody Responses
Differences between groups of Binding Antibody Responses
Change from baseline of T-Cell Mediated Immune Responses
Incidence of Solicited Local and Systemic Adverse Events
Incidence of Unsolicited Adverse Events
Show 2 moreShow less
Incidence of Immediate Adverse Events
Incidence of Medically Attended Adverse Events (MAAEs) and Adverse Events of Special Interest (AESIs)

Arms and interventions

GC4006A (Dose A)Experimental
GC4006A (Dose B)Experimental
ComirnatyActive comparator

Biologicals: GC4006A, COMIRNATY

Sites

1 site in 1 country

  • Korea University Guro HospitalSeoul, Seoul, South Korea